Literature DB >> 11277580

Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues.

M K Froberg1, D Z Gerhart, B E Enerson, C Manivel, M Guzman-Paz, N Seacotte, L R Drewes.   

Abstract

Expression of monocarboxylate transporter MCT1 was studied in archival tissues from human CNS using antibodies to the carboxyl-terminal end of MCT1. Sections of neocortex, hippocampus and cerebellum of brains from 10 adult autopsy patients who died from other than CNS disease, and from archival surgical biopsy specimens of 83 primary CNS and eight non-CNS tumors were studied. MCT1 immunoreactivity was present in microvessels and, ependymocytes of normal CNS tissues similar to that reported for MCT1 expression in rat brains. MCT1 immunoreactivity was strongest in ependymomas, hemangioblastomas and high grade glial neoplasms, and weakest in low grade gliomas. Increased MCT1 expression in high grade glial neoplasms may provide a potential therapeutic target for treatment of some CNS neoplasms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277580     DOI: 10.1097/00001756-200103260-00030

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  39 in total

Review 1.  Role of monocarboxylate transporters in human cancers: state of the art.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; João Azevedo-Silva; Margarida Casal; Fernando C Schmitt; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

2.  Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study.

Authors:  Chaim B Colen; Yimin Shen; Farhad Ghoddoussi; Pingyang Yu; Todd B Francis; Brandon J Koch; Michael D Monterey; Matthew P Galloway; Andrew E Sloan; Saroj P Mathupala
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

3.  Overexpression of HLA-DR is associated with prognosis of glioma patients.

Authors:  Jinfu Diao; Tianbao Xia; Hongwei Zhao; Jialin Liu; Bin Li; Zhiwen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells.

Authors:  Mark G Slomiany; G Daniel Grass; Angela D Robertson; Xiao Y Yang; Bernard L Maria; Craig Beeson; Bryan P Toole
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 5.  The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond.

Authors:  Andrew P Halestrap; David Meredith
Journal:  Pflugers Arch       Date:  2003-05-09       Impact factor: 3.657

6.  Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.

Authors:  Vera Miranda-Gonçalves; Mrinalini Honavar; Céline Pinheiro; Olga Martinho; Manuel M Pires; Célia Pinheiro; Michelle Cordeiro; Gil Bebiano; Paulo Costa; Isabel Palmeirim; Rui M Reis; Fátima Baltazar
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

7.  Monocarboxylate Transporter 1 in the Medial Prefrontal Cortex Developmentally Expresses in Oligodendrocytes and Associates with Neuronal Amounts.

Authors:  Mao Zhang; Ziyi Ma; Haochen Qin; Zhongxiang Yao
Journal:  Mol Neurobiol       Date:  2016-03-09       Impact factor: 5.590

8.  Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44.

Authors:  Céline Pinheiro; Rui M Reis; Sara Ricardo; Adhemar Longatto-Filho; Fernando Schmitt; Fátima Baltazar
Journal:  J Biomed Biotechnol       Date:  2010-05-04

Review 9.  Ketone bodies as a therapeutic for Alzheimer's disease.

Authors:  Samuel T Henderson
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes.

Authors:  Fátima Pérez de Heredia; I Stuart Wood; Paul Trayhurn
Journal:  Pflugers Arch       Date:  2009-10-30       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.